1. Home
  2. AMCI vs NKTX Comparison

AMCI vs NKTX Comparison

Compare AMCI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCI

AMC Robotics Corporation Common Stock

N/A

Current Price

$6.21

Market Cap

157.4M

Sector

Finance

ML Signal

N/A

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.06

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCI
NKTX
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.4M
132.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AMCI
NKTX
Price
$6.21
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$13.25
AVG Volume (30 Days)
140.7K
821.7K
Earning Date
01-01-0001
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
$6,878,315.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$1.31
52 Week High
$42.00
$2.74

Technical Indicators

Market Signals
Indicator
AMCI
NKTX
Relative Strength Index (RSI) 48.97 49.51
Support Level $5.65 $1.95
Resistance Level $6.72 $2.13
Average True Range (ATR) 0.71 0.13
MACD 0.10 -0.03
Stochastic Oscillator 51.20 25.78

Price Performance

Historical Comparison
AMCI
NKTX

About AMCI AMC Robotics Corporation Common Stock

AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: